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Abstract 
Background: Complete resection of locally advanced sigmoid colon cancer (LASCC) is sometimes difficult. Patients 
with LASCC have a dismal prognosis and poor quality of life, which has encouraged the evaluation of alternative 
multimodality treatments. This prospective study aimed to assess the feasibility and efficacy of neoadjuvant chemora‑
diotherapy (neoCRT) followed by surgery as treatment of selected patients with unresectable LASCC.
Methods: We studied the patients with unresectable LASCC who received neoCRT followed by surgery between 
October 2010 and December 2012. The neoadjuvant regimen consisted of external‑beam radiotherapy to 50 Gy and 
capecitabine‑based chemotherapy every 3 weeks. Surgery was scheduled 6–8 weeks after radiotherapy.
Results: Twenty‑one patients were included in this study. The median follow‑up was 42 months (range, 
17–57 months). All patients completed neoCRT and surgery. Resection with microscopically negative margins (R0 
resection) was achieved in 20 patients (95.2%). Pathologic complete response was observed in 8 patients (38.1%). 
Multivisceral resection was necessary in only 7 patients (33.3%). Two patients (9.5%) experienced grade 2 postopera‑
tive complications. No patients died within 30 days after surgery. For 18 patients with pathologic M0 (ypM0) disease, 
the cumulative probability of 3‑year local recurrence‑free survival, disease‑free survival and overall survival was 
100.0%, 88.9% and 100.0%, respectively. For all 21 patients, the cumulative probability of 3‑year overall survival was 
95.2% and bladder function was well preserved.
Conclusion: For patients with unresectable LASCC, preoperative chemoradiotherapy and surgery can be performed 
safely and may result in an increased survival rate.
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Background
Colorectal cancer is the third most common malignancy 
and the fourth leading cause of cancer-related death 
worldwide [1]. In China, it is the fifth most common can-
cer and the fifth leading cause of cancer death [2, 3]. At 
initial presentation, approximately 10% of patients with 
colon cancer have a primary tumor involving adjacent 
structures, also known as locally advanced disease [4, 5]. 
Like other gastrointestinal malignancies, sigmoid colon 
cancer can invade or be adherent to adjacent structures 
[6–8].
Surgery is the principal treatment of colon cancer and 
the amount of residual tumor present after surgery is an 
important predictor of survival and recurrence rate [9]. 
To achieve resections with microscopically negative mar-
gins (R0 resection), treatment of locally advanced adher-
ent colon cancer requires en-bloc multivisceral resection, 
defined as the partial or complete removal of neighbor-
ing organs to which the primary tumor is attached [6, 
7]. However, several studies have suggested that many 
patients with locally advanced colon cancer, even after 
undergoing multivisceral resection, still have an incom-
plete removal of tumor [6, 7, 10, 11]. Moreover, this 
extensive surgical procedure increases the risk of com-
plications and death. These confounding factors have 
encouraged the evaluation of alternative multimodality 
treatments.
The efficacy of neoadjuvant chemoradiotherapy 
(neoCRT) on locally advanced rectal cancer is well estab-
lished [12–17]; the efficacy of radiotherapy on locally 
advanced colon cancer, however, is not, with only a few 
studies having evaluated radiotherapy delivered in an 
adjuvant manner [18, 19]. Many patients with locally 
advanced colon cancer undergo extensive surgical resec-
tion, or their tumors are deemed unresectable without 
alternative multimodality approaches being evaluated. 
We conducted a pilot study to assess the feasibility and 
efficacy of neoCRT followed by surgery on unresectable 
locally advanced sigmoid colon cancer (LASCC). The R0 
resection rate, pathologic complete response (pCR) rate, 
organ preservation, treatment complications and survival 
were analyzed and evaluated.
Methods
Patient selection and evaluation
Patient eligibility
Patients with LASCC (defined as the primary tumor hav-
ing an inferior margin  >15  cm from the anal verge, as 
determined by rigid proctoscopy) were candidates for 
neoCRT if they met the following criteria: (1) curative 
resection was deemed impossible because preoperative 
imaging examinations showed that the tumor extensively 
involved adjacent organs/structures, such as the bladder, 
ureter, or great vessels, thus compromising a clean radial 
margin; and/or (2) curative resection was deemed impos-
sible after exploratory laparotomy. Since the primary 
objective was to assess local tumor response, patients 
with distant metastasis were also eligible. Patients with 
uncontrolled medical conditions (e.g., hypertension, dia-
betes, heart failure, or psychiatric disease) were excluded 
from the study.
Patient evaluation
Patients had to have a computed tomography (CT) scan 
of the chest and abdomen; magnetic resonance imaging 
(MRI) of the pelvis; a colonoscopy with/without endo-
scopic ultrasonography; an electrocardiogram; a com-
plete blood count; a liver function test; a renal function 
test; test of electrolyte counts; and test of baseline levels 
of carcinoembryonic antigen (CEA) and carbohydrate 
antigen 19-9. Patients were staged before neoCRT and 
after surgery based on the American Joint Committee on 
Cancer Staging System (7th edition).
Ethics, consent and permission
This study was approved by the ethics committee of Sun 
Yat-sen University Cancer Center. Before treatment, writ-
ten informed consent was obtained from all patients. We 
discussed the cases of all eligible patients at our Multidis-
ciplinary Cancer Conferences. We obtained consent from 
all patients to report individual patient data.
Study design
The primary objective of this prospective study was to 
assess the R0 resection rate. The secondary objectives 
were to assess the pCR rate, tumor down-staging, organ 
preservation, complication rates, local recurrence-free 
survival (LRFS), disease-free survival (DFS), and overall 
survival (OS). Organ preservation referred to avoiding 
extensive multivisceral resection by successful tumor 
down-staging, thus preserving the structure and function 
of nearby organs, especially the bladder.
Treatment
Radiotherapy
All patients were immobilized using an AIO Bellyboard and 
Pelvic Solution system (AIO solution, Orfit Industries, Wij-
negem, Belgium). Patients were simulated with moderately 
full bladder. CT-based simulation with 3-mm slice thick-
ness was performed. The target volumes were delineated 
according to the guidelines of the International Commis-
sion on Radiation Units and Measurements, Reports 50 and 
62. The gross tumor volume (GTV) was the macroscopic 
tumor and the enlarged lymph nodes visible on MRI or CT 
images. The clinical target volume (CTV) was the primary 
tumor with a cranio-caudal margin of 2–3  cm, enlarged 
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lymph nodes, sigmoid mesocolon and the lymphatic drain-
age regions. If the tumor invaded adjacent structures, a fur-
ther 1.5-cm isotropic margin into the involved structures 
had to be included to account for microscopic disease and 
the ischiorectal fossa had to be included to account for pos-
sible implantation metastases to the pelvic floor. The cra-
nial boundary of the CTV was located at the interspace 
between the fourth and fifth lumbar vertebrae. Planning 
target volume 1 (PTV1) covered the GTV with an isotropic 
margin of 0.6 cm. PTV2 covered the CTV with an isotropic 
margin of 0.6 cm. The prescribed dose was 50 Gy to PTV1 
and 46 Gy to PTV2 in 25 fractions, with a linear accelera-
tor adjusted to deliver an energy of 8 MV photons. Either 
3-dimensional conformal radiotherapy (3D-CRT) or inten-
sity-modulated radiotherapy (IMRT) was delivered. Organ 
constraints included a maximal dose (Dmax) to the small 
intestine of less than 54  Gy, a volume of the small intes-
tine receiving  >40  Gy (V40 to the small intestine) of less 
than 150 cm3, a volume percentage of the bladder receiv-
ing >55 Gy (V55 to the bladder) of less than 30%, a volume 
percentage of the kidneys receiving  >20  Gy (V20 to the 
kidneys) of less than 30% and a volume percentage of the 
femoral head receiving >50 Gy (V50 to the femoral head) of 
less than 5%, whenever applicable.
Chemotherapy
Medical oncologists determined the concurrent capecit-
abine chemotherapy regimen. Adjuvant chemotherapy, 
consisting of a capecitabine-based regimen, was sched-
uled for all patients regardless of pathologic tumor, node 
and metastasis (pTNM) stage.
Surgery
MRI of the pelvis, CT of the chest and abdomen, colo-
noscopy and all blood tests were repeated 5  weeks 
after neoCRT. Surgery was scheduled 6–8  weeks after 
radiotherapy. A colectomy with en-bloc removal of the 
regional lymph nodes was performed. When tumor infil-
tration or adhesion to the adjacent organs was detected 
intraoperatively, an en-bloc multivisceral resection was 
required. En-bloc multivisceral resection was defined 
as the partial or complete removal of adjacent organs 
to which the primary tumor was attached, including 
affected parts of the sigmoid colon.
Response, toxicity and complications
We defined pCR as the absence, from surgical samples, 
of malignant cells in the primary site and regional lymph 
nodes. Acute complications related to neoCRT were 
evaluated according to the Common Terminology Crite-
ria for Adverse Events (version 4.03). Postoperative com-
plications were evaluated according to the Clavien-Dindo 
classification [20].
Follow‑up
Patients were followed up every 3  months for the first 
2  years after surgery and every 6–12  months thereaf-
ter. The last follow-up was performed in October 2015. 
Surveillance included medical history, physical examina-
tion, CEA testing, colonoscopy, and CT scanning. CEA 
levels were tested and CT scans were performed every 
6 months. Colonoscopy was performed every 12 months.
Statistical analysis
Continuous data are presented as median with range. 
Categorical data are presented as proportions (%). Cumu-
lative proportions of LRFS, DFS and OS were calculated 
with Life Table methods. All statistical analyses were per-
formed with SPSS version 17 software (SPSS, Chicago, 
IL, USA).
Results
Demographics
In this study, we included 21 patients who were treated 
at Sun Yat-sen University Cancer Center between Octo-
ber 2010 and December 2012. Patient demographics 
and tumor characteristics are listed in Table 1. The study 
population included 16 men and 5 women, with a median 
age of 47 years (range, 30–74 years). Based on CT/MRI 
and endoscopic ultrasound results, the baseline pri-
mary tumor was classified as T3 in 2 patients, T4a in 7 
patients and T4b in 12 patients as well as N0 in 1 patient, 
N1 in 7 patients and N2 in 13 patients. Involved adjacent 
structures included the bladder (n = 10), ureter (n = 4), 
pelvic/abdominal wall (n = 3), uterus (n = 2), iliac ves-
sels (n  =  1) and ileum (n  =  1), with the bladder being 
the most frequently involved organ (Fig.  1a–c). Three 
patients (cases 14, 19 and 21) had hematuria and symp-
toms of bladder irritation; for these patients, bladder 
involvement was confirmed by cystoscopy.
Pre‑enrollment treatment
Tumor characteristics and treatment of the 21 patients 
in this study are listed in Table 1. Before being enrolled 
in this study, 13 patients were treatment-naïve; 7 patients 
underwent previous surgical exploration without resec-
tion of the primary tumor, including diversion of the 
gastrointestinal tract proximal to the primary tumor in 
6 patients and greater omental biopsy in 1 patient; and 
the remaining 1 patient underwent chemotherapy alone. 
Three patients received previous chemotherapy regimens 
that resulted in stable disease: 1 patient received 6 cycles 
of mFOLFOX (oxaliplatin, 5-fluorouracil and leucov-
orin); 1 received 4 cycles of mFOLFOX and 3 cycles of 
FOLFOXIRI (oxaliplatin, 5-fluorouracil, leucovorin and 
irinotecan); and 1 received 4 cycles of XELOX (capecit-
abine and oxaliplatin).
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NeoCRT and response
The neoCRT regimen that each patient received is listed 
in Table  1. Sixteen patients received 50  Gy to PTV1 
and 46  Gy to PTV2 in 25 fractions over 35  days. Five 
patients received 46  Gy to PTV2 without additional 
boost to PTV1 in order to meet the dose constraints of 
the small intestine which was adjacent to the primary 
tumor.
The chemotherapy regimens included 2–4 cycles 
of XELOX (n  =  18), 2 cycles of XELOX plus 1 cycle 
Fig. 1 The magnetic resonance imaging (MRI) scans prior to neoadjuvant chemoradiotherapy (neoCRT), after neoCRT and after colectomy in a 
patient with unresectable locally advanced sigmoid colon cancer (LASCC). MRI scan of the lower abdomen and pelvis before neoCRT (a–c), 4 weeks 
after neoCRT (d–f) and 1 month after surgical resection (g–i) show the lesion. Prior to neoCRT, the lesion measured 100 mm at the largest dimen‑
sion and invaded into the urinary bladder (long arrow). The radial margins are at risk (a–c). After neoCRT, substantial down‑sizing of the lesion and 
improvement of all the margins were observed. The upper bladder wall (short arrow) remains thick (d–f). After colectomy and partial cystectomy, 
the lesion was removed completely. Bladder structure is well preserved (arrow head) (g–i). (a, d, g, coronal T1‑weighted with contrast; b, e, h, sagit‑
tal T1‑weighted with contrast; c, f, i, cross T2‑weighted)
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of Xeloda (n  =  2) and 2 cycles of CPT11 plus Xeloda 
(n = 1).
All patients completed neoCRT within the scheduled 
time. For all patients, symptomatic improvement was 
observed and objective response was demonstrated by 
pelvic MRI after neoCRT (Fig. 1d–f).
Surgery
All patients underwent surgery according to the protocol. 
The median interval between radiotherapy and surgery 
was 8  weeks (range, 7–10  weeks). The median surgery 
time was 168 min (range, 150–450 min), with a median 
blood loss of 50  mL (range, 50–200  mL). The median 
hospital stay after surgery was 8 days (range, 7–19 days). 
Fourteen patients (66.7%) received a simple colectomy 
while preserving nearby organs. Multivisceral resec-
tion was necessary for the 7 remaining patients (33.3%): 
4 patients received colectomy plus partial cystectomy; 1 
patient received colectomy plus partial cystectomy and 
ileectomy; 1 patient received colectomy plus partial cys-
tectomy and partial ureterectomy; and 1 patient received 
colectomy plus partial ureterectomy. Of the 10 patients 
with bladder involvement before neoCRT, 6 underwent a 
partial cystectomy and 4 were able to preserve the whole 
bladder.
Adjuvant chemotherapy
The adjuvant chemotherapy regimen was individual-
ized based on previous chemotherapy and response. 
Among all 21 patients, 13 received capecitabine-based 
adjuvant chemotherapy, 1 received chemotherapy 
with FOLFIRI plus cetuximab and 7 refused adjuvant 
chemotherapy.
Outcomes
R0 resection was achieved in 20 patients (95.2%). In the 
remaining 1 patient, tumor deposits on the bladder and 
pelvic wall were found intraoperatively and the surgeons 
decided not to remove these deposits. Eight patients 
(38.1%) had a pCR (Fig. 2). The primary tumor was ypT0 
in 8 patients, ypT1 in 1 patient, ypT2 in 1 patient, ypT3 
in 9 patients, ypT4a in 1 patient and ypT4b in 1 patient. 
In all 21 patients, the lymph nodes were negative. The 
median number of examined nodes was 3 (range, 0–16 
nodes). Of the 7 patients who underwent multivisceral 
resection, only 1 had histologic evidence of tumor inva-
sion to an adjacent organ (the bladder). In the other 6 
patients, inflammatory adhesions were found.
At the time of this analysis, the median follow-up 
time was 42  months (range, 17–57  months). For the 18 
patients with ypM0 disease, the cumulative probability 
for 3-year LRFS, DFS and OS were 100%, 88.9% (95% 
confidence interval [CI]: 74.4% to 100.0%) and 100%, 
respectively (Fig. 3). The main failure pattern in the study 
was distant metastasis (liver metastasis in 1 patient and 
lung metastasis in another). For all 21 patients, the cumu-
lative probability of 3-year OS was 95.2% (95% CI: 86.2% 
to 100.0%). At last follow-up, no patient had local failure.
Treatment‑related complications
NeoCRT was generally well tolerated. The most common 
non-hematologic toxicities observed were gastrointesti-
nal disorders and hand-foot syndrome. Two patients had 
grade 2 nausea; 3 patients had grade 2 diarrhea; 1 patient 
had grade 2 hand-foot syndrome; and 1 patient had grade 
3 hand-foot syndrome. No grade 4 non-hematologic tox-
icities were observed.
Fig. 2 The pathologic findings before neoCRT and after surgery of a patient with LASCC (hematoxylin and eosin staining). a, b Pathologic examina‑
tion of the sigmoid colon biopsy before neoCRT shows typical features of a well‑differentiated adenocarcinoma: hyperplastic glandular structures 
lined by atypical epithelial cells. Mitotic figures are observed. c Postoperative pathologic examination shows lymphoid infiltrates in intestinal 
mucosa. No malignant cells are observed
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No patients died within 30  days after surgery. Cla-
vien-Dindo grade 2 postoperative complications were 
observed in 2 patients (9.5%); of these, 1 patient had pul-
monary atelectasis and hypoxia and 1 patient had ileus. 
Both patients were relieved from these complications 
after conservative management. No other significant sur-
gical complications, such as impairment of wound heal-
ing, anastomotic leakage, fistulas, or infections, were 
observed.
At last follow-up, 19 patients had an Eastern Coopera-
tive Oncology Group Performance Status score of 0–1; 
the remaining 2 patients had died of cancer. In all 10 
patients with bladder involvement at enrollment, bladder 
function was well preserved.
Discussion
The role of neoCRT in the treatment of colon cancer 
is yet to be determined. In the literature, there are only 
3 case reports [21–23] and 4 retrospective studies, 
each of which enrolled only a small number of patients 
[24–27]. In the study by Brown et al. [25, 26], neoCRT 
was delivered to 4 patients with distal sigmoid tumors 
of T4 disease or threatened circumferential resection 
margin. Adverse effects were minimal and there was 
a good tumor down-staging. In another study, Hallet 
and colleagues [27] focused on recurrent colon cancer. 
Their results indicated that neoCRT followed by mul-
tivisceral resection was a feasible option for selected 
locally recurrent adherent colon cancer and was able 
to lead to R0 resection. Cukier et al. [24] reported the 
largest size of study thus far. Thirty-three patients 
with primary locally advanced adherent colon cancer 
received neoCRT followed by multivisceral resection. 
This approach resulted in high rates of R0 resection 
and good local control. Our prospective pilot study 
demonstrated the feasibility of neoCRT in the treat-
ment of patients with unresectable LASCC. In our 
study, neoCRT achieved an R0 resection rate of 95.2% 
and a pCR rate of 38.1%; enabled satisfactory organ 
preservation; and reduced surgery-related morbid-
ity and mortality. We consider our results to be very 
encouraging.
En-bloc multivisceral resection is the standard surgical 
procedure for the removal of locally advanced adherent 
colon tumors [28]. Many studies have evaluated en-bloc 
multivisceral resection for colon cancer and the complete 
resection rates range from 40% to 93% [5–10], which for 
the lowest reported rates is not satisfactory. In our study, 
Fig. 3 Disease‑free survival (DFS) curve of the 18 patients with ypM0 (pathologic M0) sigmoid colon cancer. DFS was calculated by using Life Table 
methods. The cumulative probability for 3‑year DFS rate was 88.9%
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prior to neoadjuvant therapy, R0 resection was deemed 
impossible for all enrolled patients based on imaging or 
laparotomy findings. In 3 patients, chemotherapy prior 
to enrollment resulted only in stable disease. NeoCRT 
improved resectability and the subsequent surgeries 
achieved an excellent overall R0 resection rate of 95.2%. 
Similarly, in a study by Cukier et al. [24], 33 patients with 
primary locally advanced adherent colon cancer received 
neoCRT followed by multivisceral resection. The R0 
resection rate was 100%. Therefore, compared with mul-
tivisceral resection alone, neoCRT seems to improve 
resectability and the R0 resection rate. To our knowledge, 
residual tumor is a significant negative predictor of sur-
vival in patients with locally advanced adherent colon 
cancer; thus, improvement in the R0 resection rate could 
result in an improved survival rate.
In our study, neoCRT resulted in significant tumor 
down-sizing and down-staging. The pCR rate was as 
high as 38.1% and the pathologic nodal negative rate was 
100%. These results could be comparable with those of 
other colon cancer studies that reported a nodal posi-
tive rate of 40% to 69% [8, 29]. However, in their study 
of locally advanced adherent colon cancer after neoCRT, 
Cukier et al. [24] reported a pCR rate of 3% and a nodal 
negative rate of 79%. Both figures are lower than what we 
found in our study. Higher radiation doses and two-drug 
combination concurrent chemotherapy might have con-
tributed to this difference. In another study, for the treat-
ment of rectal cancer, neoCRT resulted in high rates of 
tumor down-staging [30]. In general, patients who expe-
rience a pCR after neoCRT have higher DFS and OS rates 
than those who do not experience a pCR [30, 31]. There-
fore, it is reasonable to assume that the final pathologic 
stage would be an important determinant in sigmoid 
colon cancer as well, meaning that patients who experi-
ence a pCR may have particularly favorable outcomes. 
However, these conclusions need to be validated by stud-
ies that have larger sample sizes and longer duration of 
follow-up.
Although multivisceral resection is the preferred sur-
gical method for removing locally advanced adherent 
colorectal tumors, it is an aggressive procedure that 
increases postoperative morbidity and mortality. The 
incidence of postoperative complications and mortality 
were reported to be 11% to 44% and 0% to 7.5%, respec-
tively [7–9]. Therefore, a secondary objective of our study 
was to evaluate the organ preservation rate after neoCRT. 
In our study, multivisceral resection after neoCRT was 
necessary in only 7 of 21 patients and tumor infiltra-
tion of an adjacent organ was confirmed histologically 
in only 1 patient. This suggests that neoCRT can mark-
edly decrease the need for multivisceral resection by 
sterilizing the peripheral extent of tumor infiltration, 
which may help to decrease postoperative morbidity and 
mortality.
According to previous studies as well as to our findings, 
the urinary bladder is the most frequently involved organ 
in patients with locally advanced colon cancer [32]. When 
tumor infiltration of the bladder is suspected, multivis-
ceral resection may include a partial or total cystectomy. 
This may account for the increased morbidity-related 
complications, which are associated with bladder repair 
or urinary diversion [33]. In our study, we observed blad-
der involvement in 10 patients. After neoCRT, the symp-
toms related to the involved bladder in these patients 
were substantially reduced and partial cystectomy was 
necessary in only 6 patients. None of the patients needed 
a total cystectomy. In all patients, the urinary structure 
and function were both well preserved, which substan-
tially improved their quality of life. One example is case 
14 (Fig. 1), a 30-year-old man who had gross hematuria 
and symptoms associated with severe bladder irritation. 
After the initial evaluation, a total cystectomy as part 
of multivisceral resection was indicated for this patient. 
However, after neoCRT, only a partial cystectomy and a 
colectomy were required. After treatment, this patient 
had a satisfactory urinary function and was spared from 
the inconvenience and psychologic pressure that a total 
cystectomy would cause. Moreover, this patient experi-
enced a pCR, which is indicative of a good prognosis.
3D-CRT or IMRT can accurately deliver radiation to 
tumors and decrease the dose to abdominal organs, such 
as the small intestine, liver and kidneys. In this study, 
chemoradiotherapy was well tolerated. All patients com-
pleted the full cycles and doses of chemoradiotherapy 
and they underwent surgery as scheduled.
We recognize that our study has some limitations. 
First, the sample size was small and the median follow-up 
period of 42 months was rather short. Second, the radia-
tion technique/dose and the chemotherapy regimen were 
not uniform in all patients. Thus, studies that include 
more patients, have a stricter control of therapy and have 
a longer follow-up period are required to better deter-
mine the efficacy of neoCRT on LASCC.
Conclusions
For patients with unresectable LASCC, we found that 
the treatment with neoCRT improved the R0 resec-
tion rate, achieved a high pCR rate, enabled satisfactory 
organ preservation and decreased surgery-related mor-
bidity and mortality. We expect that these advantages 
might lead to an improvement in survival. To validate 
our results, studies that enroll more patients and have a 
longer follow-up period are warranted.
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